It Seems Jaguar Health Inc (NASDAQ:JAGX) Will Go Up. Just Reported Less Shorted Shares

Jaguar Health, Inc. (NASDAQ:JAGX) Logo

The stock of Jaguar Health Inc (NASDAQ:JAGX) registered a decrease of 26.93% in short interest. JAGX’s total short interest was 99,300 shares in October as published by FINRA. Its down 26.93% from 135,900 shares, reported previously. With 321,400 shares average volume, it will take short sellers 0 days to cover their JAGX’s short positions. The short interest to Jaguar Health Inc’s float is 0.49%.

The stock decreased 6.65% or $0.0501 during the last trading session, reaching $0.703. About 904,239 shares traded. Jaguar Health, Inc. (NASDAQ:JAGX) has declined 97.61% since October 12, 2018 and is downtrending. It has underperformed by 97.61% the S&P500.

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. The company has market cap of $4.29 million. The Company’s products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It currently has negative earnings. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc.

More notable recent Jaguar Health, Inc. (NASDAQ:JAGX) news were published by: which released: “Jaguar Health (JAGX) Prices 1.807M Share Offering at $2/Sh –” on July 19, 2019, also with their article: “CMTL, LOOP, TXMD and SNX among midday movers – Seeking Alpha” published on September 25, 2019, published: “Key events next week – healthcare – Seeking Alpha” on September 27, 2019. More interesting news about Jaguar Health, Inc. (NASDAQ:JAGX) were released by: and their article: “Stocks That Hit 52-Week Lows On Wednesday – Benzinga” published on October 09, 2019 as well as‘s news article titled: “Savara and AIM ImmunoTech among healthcare gainers; Clovis Oncology and Neogen among losers – Seeking Alpha” with publication date: September 24, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.